Patients' experiences related to anti-viral treatment for hepatitis C

Patient Education and Counseling

Volumn 62, Issue 1, 2006, Pages 148-155

  Fraenkel, Liana ^a,b   McGraw, Sarah ^c   Wongcharatrawee, Suchat ^a,b   Garcia Tsao, Guadalupe ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c New England Research Institutes   (United Kingdom)

Author keywords

Hepatitis C; Patient expectations; Physician patient communication

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOCTOR PATIENT RELATION; FEMALE; HEALTH CARE; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; INFORMATION PROCESSING; MALE; PATIENT CARE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; SOCIAL SUPPORT;

ADAPTATION, PSYCHOLOGICAL; ANTIVIRAL AGENTS; ATTITUDE TO HEALTH; CHOICE BEHAVIOR; COMMUNICATION; CONNECTICUT; FEMALE; FOCUS GROUPS; HEALTH SERVICES NEEDS AND DEMAND; HEALTH STATUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PATIENT CARE PLANNING; PATIENT EDUCATION; PHYSICIAN-PATIENT RELATIONS; PRIMARY HEALTH CARE; QUALITATIVE RESEARCH; QUALITY OF HEALTH CARE; QUESTIONNAIRES; RISK FACTORS; SOCIAL SUPPORT; TOTAL QUALITY MANAGEMENT;

EID: 33744825764     PISSN: 07383991     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pec.2005.06.019     Document Type: Article

References (24)

1. Pessoa M.G., and Wright T.L. Hepatitis C infection in transplantation. Clin Liver Dis 1 (1997) 663-690
2. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
3. Omata M., and Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 15 (2000) E134-E140
4. Shindo M., Hamada K., Oda Y., and Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 33 (2001) 1299-1302
5. Kasahara A., Hayashi N., Mochizuki K., Takayanagi M., Yoshioka K., Kakumu S., Iijima A., Urushihara A., Kiyosawa K., Okuda M., Hino K., and Okita K. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27 (1998) 1394-1402
6. Yoshida H., Arakawa Y., Sata M., Nishiguchi S., Yano M., Fujiyama S., Yamada G., Yokosuka O., Shiratori Y., and Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123 (2002) 483-491
7. Di Bisceglie A.M., Goodman Z.D., Ishak K.G., Hoofnagle J.H., Melpolder J.J., and Alter H.J. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 14 (1991) 969-974
8. Koretz R.L., Abbey H., Coleman E., and Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Int Med 119 (1993) 110-115
9. Mattson L., Sonnerborg A., and Weiland O. Outcome of acute asymptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 13 (1993) 274-278
10. Tremolada F., Casarin C., Alberti A., Drago C., Tagger A., Ribero M.L., and Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 16 (1992) 273-281
11. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 (1997) 825-832
12. Cotler S.J., Patil R., McNutt R.A., Speroff T., Banaad-Omiotek G., Ganger D.R., Rosenblate H., Kaur S., Cotler S., and Jensen DM. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. Am J Gastroenterol 96 (2001) 2730-2736
13. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
14. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
15. Sofaer S. Qualitative methods: what are they and why use them?. Health Serv Res 34 (1999) 1101-1118
16. Krueger R.A. Focus groups: a practical guide for applied research (1994), Sage Publications, Thousand Oaks, CA
17. Crabtree B., and William M.A. A qualitative approach to primary care research: the long interview. Fam Med 23 (1991) 145-151
18. Glaser B., and Strauss A. The discovery of grounded theory: strategies for qualitative research (1967), Aldine Publishing Company, New York
19. Miles M., and Huberman A.M. Qualitative data analysis: an expanded sourcebook (1994), Sage Publications, Thousand Oaks, CA
20. Weitzman E.A. Software and qualitative research. In: Denzin N., and Lincoln Y. (Eds). Handbook of qualitative research (1999), Sage Publications, Thousand Oaks, CA
21. Roter D.L., and Hall J.A. Intervention studies with patients. Improving communication in medical visits (1993), Auburn House, Westport p. 152-9
22. Edwards A., Elwyn G., and Mullen A. Explaining risks: turning numerical data into meaningful pictures. BMJ 324 (2002) 827-830
23. Cotler S.J., Wartelle C.F., Larson A.M., Gretch D.R., Jensen D.M., and Carithers Jr. R.L. Pretreatment symptoms and dosing regimen predict side effects of interferon therapy for hepatitis C. J Viral Hepatitis 7 (2000) 211-217
24. Zickmund S., Hillis S.L., Barnett M.J., Ippolito L., and Labrecque D.R. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 39 (2004) 999-1007